Abstract:

Objective: The scope of the present study is to specify the therapeutic potential for neurodegenerative diseases through evaluating cholinesterase inhibitory, tyrosinase inhibitory, antioxidant activity of Lysimachia verticillaris (LV), and to isolate the major compounds considering of most active fraction. Material and methods: The methanolic extract (ME), and the chloroform, EtOAc, and aqueous fractions obtained from the ME of LV were used for biological activity and isolation studies. The ME and all fractions were tested for their acetylcholinesterase (AChE), butyrylcholinesterase (BChE), tyrosinase (TYR) inhibitory, antioxidant potentials using ELISA microtiter assays. Seven major compounds were isolated from active EtOAc fraction by semi-preparative High Performance Liquid Chromatography (HPLC). The structures of the compounds were elucidated by several spectroscopic methods. Results: The marked AChE inhibitory activity was observed in the EtOAc fraction (63,37 ± 1,74%), BChE inhibitory activity in the ME and EtOAc fraction (85.84 ± 3.01% and 83, 82 ± 3.93%), total phenol content in the EtOAC fraction (261,59 ± 3,95 mg equivalent of gallic acid/1 g of extract) and total flavonoid contents in the EtOAC fraction (515, 54 ± 2,80 mg equivalent of quercetin/1 g of extract), DPPH radical scavenging activity and FRAP values in the aqueous and EtOAC fractions (92,54 ± 0,67%, 92,11 ± 0,30%; 2,318 ± 0,054, 2,224 ± 0, 091, respectively). Point of view, isolation studies were carried out on the EtOAC fractions. Compounds 1-7 (Gallic acid, (+)-catechin, myricetin 3-O-arabinofuranoside, myricetin 3-O-α-rhamnopyranoside, quercetin 3-O-β-glucopyranoside, quercetin 3-O-arabinofuranoside, and quercetin 3-O-α-rhamnopyranoside, respectively) were isolated from the active EtOAc fraction. Conclusion: LV may be a potential herbal source for treatment of neurodegenerative diseases based on its strong antioxidant activity and significant cholinesterase inhibition similar to that of the reference.

Keywords: